Is Trabectedin a chemotherapy drug?

Trabectedin is usually classified as an "anti-tumor drug" in academic classification, but it is somewhat different from chemotherapy drugs in the traditional sense. Chemotherapy drugs generally refer to broad-spectrum drugs based on cytotoxicity, such as paclitaxel, cisplatin, cyclophosphamide, etc. They mainly work by interfering with the division of cancer cells. The source of trabectedin is relatively unique. It was originally a natural product extracted from ascidians and was later synthesized for clinical use.

Its mechanism of action is similar to that of classic alkylating agents. By binding toDNA grooves, it affects the DNA replication and repair process, thereby inhibiting the growth of tumor cells. Because of this, some literature includes it as an "alkylating agent chemotherapy drug" and also emphasizes its characteristics as a "new DNA binding agent".

In the clinical practice of tumor treatment, trabectedin is mainly approved for the treatment of unresectable or metastatic soft tissue sarcomas, especially patients with liposarcoma and leiomyosarcoma. Such patients often consider trabectedin only after failure or relapse of common chemotherapy drugs, so it is also called a "second-line or third-line treatment option." Different from traditional chemotherapy, trabectedin has a different side effect spectrum. For example, its impact on liver function deserves more attention, while its effect on bone marrow suppression may be relatively mild. This makes it necessary to cooperate with strict liver function monitoring and dose adjustment during clinical use.

In addition, the development path of trabectedin also reflects the trend of modern anti-cancer drugs gradually transitioning from traditional "broad-spectrum toxicity" to "targeted combination". Although it is not a molecular targeted drug and does not fall into the category of immunotherapy, it is regarded to some extent as an "evolved version of chemotherapy drugs" due to its unique mechanism of action. Therefore, from a narrow perspective, it is a chemotherapy drug; from a broad perspective, it is a type of anti-tumor drug with unique sources and special mechanism of action.

Reference materials:https://www.drugs.com/monograph/trabectedin.html